Multiple Sclerosis (MS) Secondary Progressive
9
5
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Home Based Functional Balance Intervention for Multiple Sclerosis
Senolytics for Secondary Progressive MS
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography